Salix Pharmaceuticals
 | This article needs additional citations for verification. (February 2019) |
Parent Bausch Health | | |
| Website | salix | |
|---|---|---|
Salix Pharmaceuticals, Inc. is an American specialty pharmaceutical company based in
Bridgewater, New Jersey
.
It is the largest gastroenterology-focused pharmaceutical company in the world. Salix develops prescription drugs and medical devices that prevent and treat various gastrointestinal disorders.
History
Salix was founded in 1989[1] in Sunnyvale, California by Randy W. Hamilton and Lorin K. Johnson.
From 1992 to 2001, the company was headquartered in
Palo Alto
before relocating to its current headquartered in Raleigh.
In 2003, the company survived a
Solesta
for $300M. In 2013, Salix acquired Santarus and its products Uceris (oral), Zegerid, Glumetza, Cycloset and Ruconest for $2.6B. Total sales of Salix products in 2014 were $1.1 billion.
In 2010, Salix Pharmaceuticals signed a strategic global agreement with
colon through fluorescence diagnosis. In addition to the development of Lumacan for colorectal cancer, Salix holds the exclusive right to explore and develop products for additional indications involving the diagnosis of gastrointestinal dysplasia and cancer.[3]
In February 2015,
Valeant Pharmaceuticals announced it would acquire Salix for $14.5 billion, creating the world leader in gastrointestinal drugs. The deal was completed on April 1, 2015.[4] On the final day of trading, Salix shares traded for $172.81, giving it a market capitalization
of $10.9 billion.
References
- ^ "Salix Pharmaceuticals - Company, United States - SWFI". www.swfinstitute.org. Retrieved 2020-08-19.
- ^ Salix Pharmaceuticals Board Unanimously Recommends Rejection of Axcan's Revised Offer. Business Wire, May 27, 2003.
- ^ "Agreement with Salix Pharmaceuticals for Lumacan™". photocure.com. Retrieved 6 February 2019.
- ^ "Valeant to Acquire Salix for $14.5B". Genengnews.com. 23 February 2015. Retrieved 6 February 2019.